
Quarterly report 2025-Q3
added 11-13-2025
Co-Diagnostics Revenue 2011-2026 | CODX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Co-Diagnostics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.81 M | 34.2 M | 97.9 M | 74.6 M | 215 K | 39.9 K | 7.66 K | - | 10 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 97.9 M | 7.66 K | 26.7 M |
Quarterly Revenue Co-Diagnostics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 145 K | 163 K | 50.3 K | - | 641 K | 2.66 M | 468 K | - | 2.46 M | 198 K | 602 K | - | 5.09 M | 5.02 M | 22.7 M | - | 30.1 M | 27.4 M | 20 M | - | 21.8 M | 24 M | 1.55 M | - | 41.4 K | 61.6 K | 3.4 K | - | 9.7 K | 9.7 K | 9.7 K | - | 2.6 K | 2.47 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 30.1 M | 2.47 K | 6.36 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M | ||
|
Brainsway Ltd.
BWAY
|
41 M | $ 22.96 | -0.56 % | $ 99.4 M | ||
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M | ||
|
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | ||
|
Danaher Corporation
DHR
|
23.9 B | $ 237.64 | 1.12 % | $ 174 B | ||
|
DarioHealth Corp.
DRIO
|
20.4 M | $ 12.15 | -5.81 % | $ 345 M | ||
|
Burning Rock Biotech Limited
BNR
|
508 M | $ 23.25 | -0.66 % | $ 250 M | ||
|
DexCom
DXCM
|
3.62 B | $ 66.95 | -2.16 % | $ 25.8 B | ||
|
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
30.8 M | $ 1.59 | -0.94 % | $ 2.02 M | ||
|
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M | ||
|
IQVIA Holdings
IQV
|
15.4 B | $ 243.33 | 0.06 % | $ 44.1 B | ||
|
Castle Biosciences
CSTL
|
332 M | $ 39.59 | -0.76 % | $ 1.1 B | ||
|
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M | ||
|
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | ||
|
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | ||
|
Natera
NTRA
|
820 M | $ 234.65 | -2.05 % | $ 23.1 B | ||
|
CareDx, Inc
CDNA
|
280 M | $ 17.02 | -1.16 % | $ 915 M | ||
|
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | ||
|
Pacific Biosciences of California
PACB
|
201 M | $ 1.95 | -4.66 % | $ 495 M | ||
|
Anixa Biosciences
ANIX
|
210 K | $ 3.41 | -0.29 % | $ 109 K | ||
|
Exact Sciences Corporation
EXAS
|
2.76 B | $ 102.13 | 0.34 % | $ 18.9 B | ||
|
Fulgent Genetics
FLGT
|
283 M | $ 27.84 | -0.2 % | $ 842 M | ||
|
QIAGEN N.V.
QGEN
|
2.25 B | $ 48.32 | -0.27 % | $ 10.8 B | ||
|
RadNet
RDNT
|
1.83 B | $ 77.42 | -1.22 % | $ 5.65 B | ||
|
Guardant Health
GH
|
739 M | $ 110.18 | 1.32 % | $ 13.5 B | ||
|
Aspira Women's Health
AWH
|
8.18 M | - | -6.19 % | $ 10.5 M | ||
|
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
4.37 B | $ 141.01 | -3.31 % | $ 22.4 B | ||
|
Charles River Laboratories International
CRL
|
4.05 B | $ 220.64 | 2.38 % | $ 11.3 B | ||
|
Thermo Fisher Scientific
TMO
|
42.9 B | $ 620.69 | 2.34 % | $ 237 B | ||
|
Trinity Biotech plc
TRIB
|
61.6 M | $ 0.73 | -1.13 % | $ 61.9 M | ||
|
Twist Bioscience Corporation
TWST
|
377 M | $ 35.58 | 2.42 % | $ 2.13 B | ||
|
Quest Diagnostics Incorporated
DGX
|
9.87 B | $ 175.1 | -1.49 % | $ 19.4 B | ||
|
Biodesix
BDSX
|
71.3 M | $ 5.46 | -2.15 % | $ 708 M | ||
|
Laboratory Corporation of America Holdings
LH
|
13 B | $ 252.61 | -0.81 % | $ 21.2 B | ||
|
ICON Public Limited Company
ICLR
|
5.48 B | $ 183.13 | -2.7 % | $ 15.1 B | ||
|
IDEXX Laboratories
IDXX
|
3.9 B | $ 715.47 | 0.43 % | $ 59 B | ||
|
Lantheus Holdings
LNTH
|
1.53 B | $ 67.98 | 0.19 % | $ 4.7 B | ||
|
Agilent Technologies
A
|
6.32 B | $ 148.92 | 2.17 % | $ 45.3 B | ||
|
Biomerica
BMRA
|
5.31 M | $ 2.75 | -4.84 % | $ 6.32 M | ||
|
Bioventus
BVS
|
512 M | $ 8.02 | 0.25 % | $ 502 M |